2. Difficulty waking up
A person experiencing severe intoxication may become difficult or impossible to wake.
They may not respond normally when someone calls their name or attempts to get their attention.
3. Slow or shallow breathing
This is one of the most dangerous warning signs.
Opioid-related respiratory depression can cause breathing to become dangerously slow, irregular, or shallow.
4. Unusual snoring or gurgling sounds
A person who is unconscious may produce abnormal breathing sounds.
These sounds should not be mistaken for ordinary sleep.
5. Pinpoint pupils
Very small pupils can occur during opioid intoxication.
Although this sign is not present in every case, it can help emergency responders identify a possible opioid-related emergency.
6. Blue or gray lips and skin
A bluish or gray appearance around the lips, face, or fingertips can indicate inadequate oxygen circulation.
This requires immediate emergency attention.
What Should Someone Do If These Symptoms Appear?
If a person becomes unresponsive or develops dangerously slow breathing after taking an unknown substance, emergency medical assistance should be requested immediately.
In the United States, call 911.
If opioid poisoning is suspected, naloxone may help reverse opioid-related respiratory depression. It should be administered according to its instructions when available.
However, naloxone does not replace emergency medical care.
Even if the person begins responding, further medical assessment is necessary because symptoms can return or other complications may be present.
If the person is breathing normally but unconscious, place them in the recovery position when appropriate and follow emergency dispatchers' instructions.
If they are not breathing normally, begin CPR and follow the dispatcher's guidance.
The most important point is not to wait for the person to recover naturally.
An unconscious person is experiencing a medical emergency.
Why Are These Products So Easy to Find?
One of the most troubling aspects of the kratom debate is the way some concentrated products are presented to consumers.
Many are packaged to resemble ordinary wellness supplements.
Some appear similar to energy products.
Others are sold as small drink shots, chewable tablets, or colorful gummies.
A consumer unfamiliar with the chemistry may not immediately recognize that a product contains a potent opioid-like compound.
The Influence of Marketing
Products containing 7-OH have been marketed using language associated with relaxation, energy, discomfort relief, and mood enhancement.
Such descriptions can make them appear less concerning than conventional medications.
The problem is that marketing language does not establish medical safety.
A product described as natural, plant-based, or wellness-oriented can still contain pharmacologically powerful ingredients.
The FDA has warned that some companies have marketed 7-OH products with claims involving pain relief, anxiety, and other medical conditions without adequate evidence that the products are safe or effective.
The agency has also issued warning letters to companies marketing products containing concentrated 7-OH.
The Problem With Unclear Labels
Consumers may encounter several different names for related compounds.
These include:
-
7-hydroxymitragynine.
-
7-OH.
-
7-OHMG.
-
7-HMG.
-
Mitragynine.
-
Kratom extract.
Although these names are related, they should not be treated as interchangeable.
A product containing ordinary kratom leaf material is not necessarily equivalent to a concentrated 7-OH preparation.
Consumers should be particularly cautious when a package does not clearly explain its ingredients, concentrations, or manufacturing information.
An attractive package does not guarantee quality.
Likewise, a label stating that a product has been tested does not automatically establish that it has been evaluated and approved by a government health authority.
What Has the FDA Said About 7-OH Products?
The growing availability of concentrated 7-OH products has attracted significant attention from American health authorities.
In July 2025, the FDA announced warning letters involving companies that marketed products containing the compound.
The agency explained that concentrated 7-OH products were not lawful dietary supplements or approved food ingredients under the applicable federal standards.
It also emphasized that there were no FDA-approved medications containing 7-OH.
The agency's concerns included the potential for addiction, withdrawal, respiratory depression, and other serious health effects.
Why the FDA Distinguishes Between Kratom Leaves and Concentrated 7-OH
This distinction deserves particular attention.
The FDA's concerns about concentrated 7-OH products should not be interpreted as evidence that every traditional kratom preparation has the same chemical composition or risk profile.
Natural kratom leaves contain several alkaloids, with mitragynine generally being the dominant one.
7-OH is normally present in much smaller amounts.
Some commercial products, however, are intentionally enhanced or concentrated to increase the amount of 7-OH.
This changes the potential exposure.
The agency has therefore focused particular attention on products containing added or enhanced levels of the compound.
In October 2026, the federal regulatory discussion developed further.
The DEA published notices of intent concerning certain kratom-derived compounds, following updated scientific recommendations regarding concentrated 7-OH and mitragynine pseudoindoxyl products.
The proposed approach sought to distinguish concentrated formulations from products whose chemical composition more closely resembles natural botanical kratom.
These developments demonstrate that the regulatory situation remains active and should not be reduced to a simple claim that every kratom product is subject to an identical nationwide restriction.
Why Regulation Matters
Regulation is important because consumers need reliable information about what they are purchasing.
A stronger regulatory framework can help address several problems:
-
Inaccurate ingredient declarations.
-
Products containing unexpectedly high concentrations.
-
Unsubstantiated health claims.
-
Inadequate manufacturing controls.
-
Poorly documented product testing.
-
Marketing that may appeal to inexperienced consumers.
However, regulation alone cannot eliminate every risk.
Consumers must also understand that an unfamiliar substance can have serious effects even when it is sold in a familiar retail environment.
The Dangers of Combining Herbal Products With Other Substances
Another important issue is the possibility of interactions.
People sometimes consume several products without realizing that their effects may overlap.